Clovis Oncology will look to pay out a higher level of milestone payments, but at a later date, to Pfizer for its licensed PARP inhibitor, as it looks to shore…

The FDA has approved its third biosimilar. This time, it’s for the autoimmune treatment Enbrel, which had $9.5 billion in global sales last year.

California biotech Rigel Pharmaceuticals has posted positive new late-stage data for its experimental thrombocytopenia treatment and says it is eyeing a 2017…

Neurocrine Biosciences has sent off an NDA for its experimental med earlier than analysts had reckoned as it seeks U.S. approval for treating twitches of the…

Immuno-oncology antibody company Leap Therapeutics has reverse merged with Israeli public wound care player Macrocure.

The Asian unit of perpetual life science backer OrbiMed has led a modest $9.7 million first round for biotech CBT Pharmaceuticals as it looks to build up its c…

Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.

CTI BioPharma, still under a clinical hold enforced by the FDA back in February for its investigational JAK2 inhibitor candidate pacritinib, has posted new…